1. The composition of the intensive penetration of the starting drug (CIP) containing a structure selected from the group consisting of: in Fig.5, structure L, structure L-3 and structure L-4: including stereoisomers and pharmaceutically acceptable salts of these compounds, where : T is selected from the group consisting of: L is selected from the group consisting of the absence of a substituent, O, S, -N (L) -, -N (L) -CH-O, -N (L) -CH-N (L ) -, -O-CH-O-, -O-CH (L) -O and -S-CH (L) -O-； L is selected from the group consisting of the absence of a substituent, C = O, C = S ,, and L is selected from the group consisting of the absence of a substituent, N, NO, NN (L), NS, NO-CH-O, NS-CH-O, NL, NOL, NN (L) -L and L； each L and L is independently selected from the group consisting of the absence of a substituent, H, -CHCOOL, substituted and unsubstituted alkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocycloalkyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted alkoxyl, substituted and unsubstituted alkylthio, substituted and unsubstituted alkylamino, substituted and unsubstituted perfluoroalkyl, and substituted and unsubstituted halogenated, any of the carbon atoms and hydrogen and may, in turn, be independently replaced by O, S, P, NL or any other pharmaceutically acceptable group； F is selected from the group consisting of F1 and F2； F1 is selected from the group consisting of: F2 is selected from the group consisting of: F3 is selected from the group consisting of: F4 is selected from the group consisting of: each Y and Y-Y are independently selected from the group consisting of H, Cl, F, Br, I, CN, R, CHC≡C, CR≡C, P (O) OR, CF, CFO, CH, CFCF, R, R, R, R, CFCFO, CHCH, CHCHCH, (CH) CH, (CH) CHCH, CHCHCH (CH), (CH) C, CH, CH, CHCO, CHCHCO, RCO, CHOC (= O), CHCHOC (= O), ROC (= O), RC (= NOR), RC (= NR), CHCOO, RCOO, RCOOCH, RNHCOOCH, CHCOS, CHO, RO, HO, RO, CFCHSCH, CHCl, CH
